Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 05.01.18 in Vol 4, No 1 (2018): Jan-Mar

This paper is in the following e-collection/theme issue:

Works citing "Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis"

Michael S Sinha, Clark C Freifeld, John S Brownstein, Macarius M Donneyong, Paula Rausch, Brian M Lappin, Esther H Zhou, Gerald J Dal Pan, Ajinkya M Pawar, Thomas J Hwang, Jerry Avorn, Aaron S Kesselheim

JMIR Public Health Surveill 2018 (Jan 05); 4(1):e1 

According to Crossref, the following articles are citing this article (DOI 10.2196/publichealth.7823):

(note that this is only a small subset of citations)

  1. Lang SJ, Böhringer D, Bach M, Reinhard T. Analysis of user behavior on the website of a university eye hospital in Germany. Medicine 2020;99(30):e21348
    CrossRef
  2. . Impact of social media on the US FDA alerts for zolpidem. Reactions Weekly 2018;1685(1):6
    CrossRef
  3. Mazhar H, Foster BC, Necyk C, Gardiner PM, Harris CS, Robaey P. Natural Health Product–Drug Interaction Causality Assessment in Pediatric Adverse Event Reports Associated with Attention-Deficit/Hyperactivity Disorder Medication. Journal of Child and Adolescent Psychopharmacology 2020;30(1):38
    CrossRef
  4. Fabbri A, O'Keeffe M, Moynihan R, Møllebæk M, Mohammad A, Bhasale A, Puil L, Mintzes B. Media coverage of drug regulatory agencies' safety advisories: A case study of citalopram and denosumab. British Journal of Clinical Pharmacology 2020;86(7):1416
    CrossRef
  5. Borchert JS, Wang B, Ramzanali M, Stein AB, Malaiyandi LM, Dineley KE. Adverse Events Due to Insomnia Drugs Reported in a Regulatory Database and Online Patient Reviews: Comparative Study. Journal of Medical Internet Research 2019;21(11):e13371
    CrossRef
  6. de Vries E, Denig P, de Vries ST, Monster TBM, Hugtenburg JG, Mol PGM. Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands. Drug Safety 2020;43(7):677
    CrossRef
  7. . RETRACTED ARTICLE: Digital Ethnography of Zoophilia — A Multinational Mixed-Methods Study. Journal of Sex & Marital Therapy 2019;45(1):1
    CrossRef
  8. Pappa D, Stergioulas LK. Harnessing social media data for pharmacovigilance: a review of current state of the art, challenges and future directions. International Journal of Data Science and Analytics 2019;8(2):113
    CrossRef
  9. Kesselheim AS, Sinha MS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Avorn J, Dal Pan GJ. Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug Safety 2019;42(11):1287
    CrossRef
  10. Geller AI, Zhou EH, Budnitz DS, Lovegrove MC, Dal Pan GJ. Changes in emergency department visits for zolpidem‐attributed adverse drug reactions after FDA Drug Safety Communications. Pharmacoepidemiology and Drug Safety 2020;29(3):352
    CrossRef
  11. Lim SY, Bolster MB. Challenges in Optimizing Medical Education for Rheumatologists. Rheumatic Disease Clinics of North America 2019;45(1):127
    CrossRef
  12. Kesselheim AS, Sinha MS, Rausch P, Lu Z, Tessema FA, Lappin BM, Zhou EH, Dal Pan GJ, Zwanziger L, Ramanadham A, Loughlin A, Enger C, Avorn J, Campbell EG. Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey. The Journal of Law, Medicine & Ethics 2019;47(3):430
    CrossRef
  13. Gachloo M, Wang Y, Xia J. A review of drug knowledge discovery using BioNLP and tensor or matrix decomposition. Genomics & Informatics 2019;17(2):e18
    CrossRef
  14. Schiro JL, Shan LC, Tatlow-Golden M, Li C, Wall P. #Healthy: smart digital food safety and nutrition communication strategies—a critical commentary. npj Science of Food 2020;4(1)
    CrossRef
  15. Kajetanowicz A, Kajetanowicz A. PROS AND CONS OF TECHNOLOGY FOR PATIENTS. Wiadomości Lekarskie 2019;72(6):1178
    CrossRef
  16. Radawski CA, Hammad TA, Colilla S, Coplan P, Hornbuckle K, Freeman E, Smith MY, Sobel RE, Bahri P, Arias AE, Bennett D. The utility of real‐world evidence for benefit‐risk assessment, communication, and evaluation of pharmaceuticals: Case studies. Pharmacoepidemiology and Drug Safety 2020;29(12):1532
    CrossRef
  17. . The Use of Real‐World Data to Assess the Impact of Safety‐Related Regulatory Interventions. Clinical Pharmacology & Therapeutics 2022;111(1):98
    CrossRef
  18. Coca JR, Coca-Asensio R, Esteban Bueno G. Socio-historical analysis of the social importance of pharmacovigilance. Frontiers in Sociology 2022;7
    CrossRef
  19. Bahri P, Bowring G, Edwards BD, Anton C, Aronson JK, Caro-Rojas A, Hugman BPJ, Mol PG, Trifirò G, Ilic K, Daghfous R, Fermont I, Furlan G, Gaissmaier W, Geer MI, Hartigan-Go KY, Houÿez F, Neth H, Norgela G, Oppamayun Y, Raynor DKT, Bouhlel M, Santoro F, Sultana J. Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance. Drug Safety 2023;46(6):517
    CrossRef
  20. Litvinova O, Matin FB, Matin M, Zima-Kulisiewicz B, Tomasik C, Siddiquea BN, Stoyanov J, Atanasov AG, Willschke H. Patient safety discourse in a pandemic: a Twitter hashtag analysis study on #PatientSafety. Frontiers in Public Health 2023;11
    CrossRef

According to Crossref, the following books are citing this article (DOI 10.2196/publichealth.7823):

  1. . Communicating about Risks and Safe Use of Medicines. 2020. Chapter 1:1
    CrossRef